Alphabet Q2 Earnings Beat Estimates as AI Spending, Google Cloud Growth Fuel Outlook 
Intel, AMD Seek Long-Term China Server CPU Deals as AI Demand Drives Supply Crunch 
Domino’s Weighs Appeal After Australian Court Rules Workers Were Misled on Pay 
Pakistan Seeks $10 Billion U.S. Exchange Stabilization Fund to Boost Forex Reserves 
Gold Price Climbs Above $4,130 as Middle East Tensions Boost Safe-Haven Demand 
Saudi Oil Tankers Reverse Course as Houthi Threats Disrupt Red Sea Shipping 
Japan’s Nikkei Slides Over 2% as Alphabet Selloff Sparks AI Spending Concerns 
IBM Q2 Earnings Miss Estimates as Software Growth Offsets Infrastructure Weakness 
Alaska Air Q3 Outlook Misses Estimates as Higher Fuel Costs Weigh on Profit Forecast 
Rubio Rejects AI ‘Kill Switch’ Claims as U.S. Defends American Technology Abroad 
Oil Prices Rise as Houthi Attacks on Saudi Tankers Heighten Middle East Supply Fears 
Coca-Cola Raises Diet Coke Prices in India as Iran Conflict Disrupts Can Supply 
AMD Unveils Helios AI Servers to Challenge Nvidia as OpenAI Adopts New Platform 
South Korea Q2 GDP Beats Forecasts as AI Chip Exports Drive Growth 
India FMCG Q1 Earnings Preview: Higher Input Costs Likely to Weigh on Profit Margins 
Japan Yen Slides Past 163 as Middle East Tensions Lift US Dollar, Oil Prices 
US Dollar Pauses Rally as Middle East Tensions Support Safe-Haven Demand 
Samsung Biologics is expanding its CMO or contract manufacturing organization business, and as part of its plans, it is constructing its very first overseas production plant in the United States.
On Monday, June 13, Samsung Biologics’ chief executive officer, John Rim, shared that they are considering several locations for the facility. He said that the strongest candidates for their CMO site are Texas, North Carolina, California, and Washington.
According to The Korea Herald, Samsung Biologics is looking into these places more because many of the major bio companies’ facilities are also operating in the mentioned US states. At this time, the company has not yet made any decision and carefully reviewing the areas to choose the best option.
“We are certainly expanding and the Plant 4 will begin partial operation in October, adding a 60,000-liter production capacity,” the Samsung Biologics’ CEO told the media during the press meeting for the 2022 BIO International Convention in San Diego, California. “By the second quarter of next year, it will have a 180,000-liter production capacity.”
While planning to build its first manufacturing plant abroad, Samsung Biologics has already set up its fourth factory in Songdo, Incheon, in South Korea. Once this facility starts operating at its full capacity, it is expected to boost production.
All in all, the four plants should produce 620,000 liters of products for around 30% of the global demand. It was said that Samsung Biologics’ Plant 4 currently has the biggest CMO production capacity in the world, with 256,000 liters of products in a single facility.
Rim revealed that they are also aiming to build the fifth and sixth factories in South Korea, and this is why they are buying more land in Incheon. The purchases were originally expected to be completed by the end of May, but the authorities could not sign the contract because the government officials who are in charge, which are the mayor and commissioner of the Incheon Free Economic Zone, have changed due to the local elections that was held earlier this month.
Finally, the Samsung Biologics chief said that they still plan to go ahead with the construction of Plant 5 and 6. However, they will not be monitoring the supply and demand trends to see if there is still a need to build more factories.
